Eif2B3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | EIF2B3 |
|---|---|
| Full Name | Eukaryotic Translation Initiation Factor 2B Subunit Gamma |
| Chromosomal Location | 1p34.2 |
| NCBI Gene ID | 8891 |
| OMIM | 606921 |
| Ensembl ID | ENSG00000111671 |
| UniProt ID | Q9UII2 |
| Associated Diseases | Vanishing White Matter Disease, Leukoencephalopathy |
EIF2B3 (Eukaryotic Translation Initiation Factor 2B Subunit Gamma) is a critical gene encoding one of the five subunits of eIF2B, the guanine nucleotide exchange factor that recycles eIF2-GDP to eIF2-GTP. This process is essential for translational initiation in all eukaryotic cells.
EIF2B3 mutations are associated with vanishing white matter disease (VWM), an autosomal recessive leukoencephalopathy. The gene is ubiquitously expressed with high levels in brain white matter.
EIF2B3 encodes the gamma subunit of eukaryotic translation initiation factor 2B (eIF2B), which serves as the essential guanine nucleotide exchange factor (GEF) for eIF2. The eIF2B complex catalyzes the regeneration of active eIF2-GTP from the inactive eIF2-GDP complex, a critical step in translational initiation[1].
The gamma subunit is one of the core structural components of the eIF2B heterodecamer. This large multi-subunit complex contains two copies each of five different subunits (alpha, beta, gamma, delta, epsilon). The gamma subunit contributes to the stability of the complex and participates in the catalytic GEF activity. eIF2B is centrally involved in the integrated stress response (ISR), where cellular stress leads to phosphorylation of eIF2alpha, which allosterically inhibits eIF2B activity[2].
Mutations in EIF2B3 cause vanishing white matter disease (VWM), an autosomal recessive disorder representing the most common inherited leukodystrophy. Clinical manifestations include progressive cerebellar ataxia, spasticity, optic atrophy, and cognitive decline. The disease follows a chronic progressive course with episodic deterioration triggered by minor infections or head trauma[3].
Pathogenic variants in EIF2B3 result in partial loss of eIF2B function, impairing the integrated stress response in glial cells. This vulnerability is particularly pronounced in oligodendrocytes, which are highly sensitive to ER stress and require robust protein homeostasis mechanisms for myelin synthesis and maintenance[4].
EIF2B3 is ubiquitously expressed with highest expression in the brain, particularly in white matter. The protein localizes to the cytoplasm of all cell types, with abundant expression in oligodendrocytes and astrocytes. This widespread expression reflects the fundamental role of eIF2B in protein synthesis regulation across all cell types[5].
The study of Eif2B3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.